These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 11009049)

  • 21. A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes.
    Heise T; Pieber TR; Danne T; Erichsen L; Haahr H
    Clin Pharmacokinet; 2017 May; 56(5):551-559. PubMed ID: 28205039
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Clinical pharmacokinetics and pharmacodynamics of insulin aspart.
    Lindholm A; Jacobsen LV
    Clin Pharmacokinet; 2001; 40(9):641-59. PubMed ID: 11605714
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Faster-acting insulin aspart provides faster onset and greater early exposure vs insulin aspart in children and adolescents with type 1 diabetes mellitus.
    Fath M; Danne T; Biester T; Erichsen L; Kordonouri O; Haahr H
    Pediatr Diabetes; 2017 Dec; 18(8):903-910. PubMed ID: 28165180
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A comparison of the pharmacodynamic profiles of jet-injected regular human insulin versus conventionally administered insulin aspart in healthy volunteers.
    Engwerda EEC; Tack CJ; de Galan BE
    Diabetes Res Clin Pract; 2016 Nov; 121():86-90. PubMed ID: 27662042
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.
    von Mach MA; Brinkmann C; Hansen T; Weilemann LS; Beyer J
    Exp Clin Endocrinol Diabetes; 2002 Nov; 110(8):416-9. PubMed ID: 12518253
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart.
    Pieber TR; Svehlikova E; Brunner M; Halberg IB; Due Thomsen KM; Haahr H
    Diabetes Obes Metab; 2019 Sep; 21(9):2068-2075. PubMed ID: 31069935
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are insulin analogues an unavoidable necessity for the treatment of type 2 diabetes in developing countries? The case of Jordan.
    Hyassat D; Al Shekarchi N; Jaddou H; Liswi M; El-Khateeb M; Ajlouni KM
    East Mediterr Health J; 2015 Dec; 21(10):729-35. PubMed ID: 26750163
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Improved postprandial glycemic control with insulin aspart. A randomized double-blind cross-over trial in type 1 diabetes.
    Lindholm A; McEwen J; Riis AP
    Diabetes Care; 1999 May; 22(5):801-5. PubMed ID: 10332685
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The pharmacokinetic and pharmacodynamic properties of biphasic insulin Aspart 70 (BIAsp 70) are significantly different from those of biphasic insulin Aspart 30 (BIAsp 30).
    Bott S; Tusek C; Heinemann L; Friberg HH; Heise T
    Exp Clin Endocrinol Diabetes; 2005 Oct; 113(9):545-50. PubMed ID: 16235159
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The Distinct Prandial and Basal Pharmacodynamics of IDegAsp Observed in Younger Adults Are Preserved in Elderly Subjects with Type 1 Diabetes.
    Brunner M; Pieber T; Korsatko S; Kojzar H; Svendsen AL; Haahr H
    Drugs Aging; 2015 Jul; 32(7):583-90. PubMed ID: 26088815
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacodynamic and pharmacokinetic properties of a premixed 85/15 human insulin preparation.
    Mudaliar SR; Mohideen P; Baxi SC; Joyce M; Armstrong DA; Strange P; Henry RR
    Clin Ther; 2001 Mar; 23(3):404-12. PubMed ID: 11318075
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes.
    Kochba E; Levin Y; Raz I; Cahn A
    Diabetes Technol Ther; 2016 Sep; 18(9):525-31. PubMed ID: 27500713
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.
    Lepore M; Pampanelli S; Fanelli C; Porcellati F; Bartocci L; Di Vincenzo A; Cordoni C; Costa E; Brunetti P; Bolli GB
    Diabetes; 2000 Dec; 49(12):2142-8. PubMed ID: 11118018
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Improved Postprandial Glycemic Control with Faster-Acting Insulin Aspart in Patients with Type 1 Diabetes Using Continuous Subcutaneous Insulin Infusion.
    Bode BW; Johnson JA; Hyveled L; Tamer SC; Demissie M
    Diabetes Technol Ther; 2017 Jan; 19(1):25-33. PubMed ID: 28055230
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Insulin degludec/insulin aspart produces a dose-proportional glucose-lowering effect in subjects with type 1 diabetes mellitus.
    Heise T; Nosek L; Klein O; Coester H; Svendsen AL; Haahr H
    Diabetes Obes Metab; 2015 Jul; 17(7):659-64. PubMed ID: 25772444
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacokinetic and prandial pharmacodynamic properties of insulin degludec/insulin aspart in children, adolescents, and adults with type 1 diabetes.
    Biester T; Danne T; Bläsig S; Remus K; Aschemeier B; Kordonouri O; Bardtrum L; Haahr H
    Pediatr Diabetes; 2016 Dec; 17(8):642-649. PubMed ID: 26782928
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Premixed insulin analogues for the treatment of diabetes mellitus.
    Garber AJ
    Drugs; 2006; 66(1):31-49. PubMed ID: 16398567
    [TBL] [Abstract][Full Text] [Related]  

  • 38. 28-week, randomized, multicenter, open-label, parallel-group phase III trial to investigate the efficacy and safety of biphasic insulin aspart 70 thrice-daily injections vs twice-daily injections of biphasic insulin aspart 30 in patients with type 2 diabetes.
    Kadowaki T; Nishida T; Kaku K
    J Diabetes Investig; 2010 Jun; 1(3):103-10. PubMed ID: 24843416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of Premixed Human Insulin 30/70 to Biphasic Aspart 30 in Well-Controlled Patients with Type 2 Diabetes Using Continuous Glucose Monitoring.
    Margaritidis C; Karlafti E; Kotzakioulafi E; Kantartzis K; Tziomalos K; Kaiafa G; Savopoulos C; Didangelos T
    J Clin Med; 2021 May; 10(9):. PubMed ID: 34063071
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Lispro Mix25 insulin as premeal therapy in type 2 diabetic patients.
    Koivisto VA; Tuominen JA; Ebeling P
    Diabetes Care; 1999 Mar; 22(3):459-62. PubMed ID: 10097929
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.